Overview
- biosynthesis of catecholamines is done in 3 (4) steps
TYROSINE
| tyrosine hydroxylase
DOPA
| DOPA decarboxylase
DOPAMINE
| dopamine beta-hydroxylase
NORADRENALINE
| phenylethanolamide N-methyltransferase (“PNMT”)
ADRENALINE
- , thus there are 3 (4) enzymes involved in catecholamine biosynthesis
ENZYME NAME
DESCRIPTION
TYROSINE HYDROXYLASE
- the rate-limiting step
- located in the cytoplasm of sympathetic postsynaptic neurons
DOPA DECARBOXYLASE
DOPAMINE BETA-HYDROXYLASE
PNMT
- general enzyme located in the cytoplasm of most cells
- catalyses decarboxylation of aromatic amino acids
- located in the synaptic vesicles of postsynaptic sympathetic nerve terminals
- located in the a-cells of the adrenal medulla
Relevant Drugs
- 3 types
DRUG NAME
DESCRIPTION
ALPHA-METHYLTYROSINE
METHYLDOPA
General information
- a tyrosine hydroxylase inhibitor
- inhibits tyrosine hydroxylase, thus causing inhibition of catecholamine synthesis
Clinical use
- treatment of pheochromocytoma (a catecholamine-
producing adrenal medullary tumor)
Side effects
- hypotension (due to vasodilation)
- drowsiness
General information
- a central DOPA decarboxylase inhibitor (may cross the blood-brain barrier)
- alternate substrate for DOPA decarboxylase , thus displacing DOPA from the active site of DOPA decarboxylase and following inhibition of catecholamine synthesis
- is converted by DOPA decarboxylase to methylnoradrenalin (a selective alpha-2 agonist, see 19)
Clinical use
- treatment of hypertension during pregnancy (by
inhibition of the sympathetic nuclei of the brainstem)
Side effects
- same as alpha-methyltyrosine (see above)
CARBIDOPA
- impotency
- hypersensitivity reactions
General information
- a peripheral DOPA decarboxylase inhibitor (may not
pass the blood-brain barrier)
Clinical use
- treatment of parkinson’s disease (by inhibition of the
use of DOPA for catecholamine synthesis in
peripheral neurons, thus freeing it for restorement of
the dopaminergic pathways of the brain
- biosynthesis of catecholamines is done in 3 (4) steps
TYROSINE
| tyrosine hydroxylase
DOPA
| DOPA decarboxylase
DOPAMINE
| dopamine beta-hydroxylase
NORADRENALINE
| phenylethanolamide N-methyltransferase (“PNMT”)
ADRENALINE
- , thus there are 3 (4) enzymes involved in catecholamine biosynthesis
ENZYME NAME
DESCRIPTION
TYROSINE HYDROXYLASE
- the rate-limiting step
- located in the cytoplasm of sympathetic postsynaptic neurons
DOPA DECARBOXYLASE
DOPAMINE BETA-HYDROXYLASE
PNMT
- general enzyme located in the cytoplasm of most cells
- catalyses decarboxylation of aromatic amino acids
- located in the synaptic vesicles of postsynaptic sympathetic nerve terminals
- located in the a-cells of the adrenal medulla
Relevant Drugs
- 3 types
DRUG NAME
DESCRIPTION
ALPHA-METHYLTYROSINE
METHYLDOPA
General information
- a tyrosine hydroxylase inhibitor
- inhibits tyrosine hydroxylase, thus causing inhibition of catecholamine synthesis
Clinical use
- treatment of pheochromocytoma (a catecholamine-
producing adrenal medullary tumor)
Side effects
- hypotension (due to vasodilation)
- drowsiness
General information
- a central DOPA decarboxylase inhibitor (may cross the blood-brain barrier)
- alternate substrate for DOPA decarboxylase , thus displacing DOPA from the active site of DOPA decarboxylase and following inhibition of catecholamine synthesis
- is converted by DOPA decarboxylase to methylnoradrenalin (a selective alpha-2 agonist, see 19)
Clinical use
- treatment of hypertension during pregnancy (by
inhibition of the sympathetic nuclei of the brainstem)
Side effects
- same as alpha-methyltyrosine (see above)
CARBIDOPA
- impotency
- hypersensitivity reactions
General information
- a peripheral DOPA decarboxylase inhibitor (may not
pass the blood-brain barrier)
Clinical use
- treatment of parkinson’s disease (by inhibition of the
use of DOPA for catecholamine synthesis in
peripheral neurons, thus freeing it for restorement of
the dopaminergic pathways of the brain
No comments:
Post a Comment